University of Miami

Recent publications and citations

Top Concepts

Top subject area publications in last 5 years

Collaboration Analysis

Publications from 2021 to 2026

Latest Publications

Showing 10 of 19,234 papers

Research Article
10.1016/j.pec.2026.109609

Owning the moment: A call for humanism in medicine to address complex chronic illness.

Aug 01, 2026
Patient education and counseling
Ana M Palacio

Research Article
10.1016/j.forsciint.2026.112916

Prevalence of N,N-Dimethylpentylone in forensic toxicology casework: Aretrospective study and trends in the state of Florida.

Jul 01, 2026
Forensic science international
Marco Ballotari + 8 more +8

Research Article
10.1016/j.ecolmodel.2026.111575

Modeling the spatial dynamics of phage-driven perturbations in a bacterial cross-feeding system

Jun 01, 2026
Ecological Modelling
Parsa Pakzad + 1 more +1

Research Article
10.1016/j.envpol.2026.127968

Cellular responses of human Muller glia exposed to test dust pollution.

May 01, 2026
Environmental pollution (Barking, Essex : 1987)
Maumita Datta + 3 more +3

Research Article
10.1200/jco-25-01489

Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.

May 01, 2026
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Benjamin Besse + 30 more +30

RET fusions appear in 1%-2% of non-small cell lung cancers (NSCLCs). The results from the ARROW study (ClinicalTrials.gov identifier: NCT03037385) supported US Food and Drug Administration approval of pralsetinib, an oral selective RET inhibitor, for metastatic RET-altered NSCLC and RET fusion-positive thyroid cancers. ARROW was a phase I/II open-label study of pralsetinib 400 mg once daily in RET fusion-positive NSCLCs. Coprimary end points were overall response rate (ORR) and safety. Key secondary end points included duration of response, progression-free survival, and overall survival (OS). At data lock (May 20, 2024), 281 patients initiated pralsetinib (median treatment duration, 15.0 months). ORR (measurable disease patients; n = 259) was 78% (95% CI, 69 to 86) for treatment-naïve patients and 63% (95% CI, 54 to 71) for prior platinum-based chemotherapy patients. Median OS was 44.3 months (95% CI, 30.9 to 53.1), 50.1 months (95% CI, 28.3 to not reached) in treatment-naïve patients, and 39.7 months (95% CI, 27.8 to 53.2) in prior platinum patients. Common grade ≥3 treatment-related adverse events were anemia (21%), hypertension (15%), and decreased neutrophils (13%). Three treatment-related deaths occurred (pneumonia, n = 2; interstitial lung disease and rhabdomyolysis, n = 1 each). Safety was consistent with previous ARROW reports; no hypersensitivity was reported in patients receiving prior immunotherapies. Pralsetinib produced robust, durable responses with manageable safety in treatment-naïve and previously treated patients with RET fusion-positive NSCLCs, confirming previous findings with longer follow-up.

Research Article
10.1016/j.jid.2025.11.012

Scratch and tickle: Divergent cutaneous sensations with common neurobiological roots.

May 01, 2026
The Journal of investigative dermatology
Nicole Khalil + 2 more +2

Research Article
10.1053/j.gastro.2026.01.041

Development of the Rome V Diagnostic Questionnaires.

May 01, 2026
Gastroenterology
Olafur S Palsson + 6 more +6

Front Matter
1
10.1016/j.amjsurg.2026.116831

Rethinking Global Surgery research: Role of mixed-methods studies.

May 01, 2026
American journal of surgery
Nikita Manish Shah + 2 more +2

Addendum
10.1245/s10434-026-19230-y

Publisher Correction: Prognostic Value of Non-nodal Regional Metastases in Predicting Sentinel Lymph Node Status in Cutaneous Melanoma: Multicenter Analysis of the Sentinel Lymph Node Working Group Database.

May 01, 2026
Annals of surgical oncology
Nazia Riaz + 15 more +15

Discussion
10.1016/j.jmig.2025.08.025

Regarding "Endometrial Biopsy Versus no Endometrial Biopsy With a Normal Appearing Cavity During In-Office Hysteroscopy for Postmenopausal Bleeding: A Randomized Controlled Trial".

May 01, 2026
Journal of minimally invasive gynecology
Jose Carugno + 1 more +1